26swdgu17 10.3205/26swdgu17 urn:nbn:de:0183-26swdgu179 Meeting Abstract Wenzel Wenzel Mike M

Universitätsklinikum Frankfurt, Urologie, Frankfurt, Deutschland

author Büttner Büttner T. T

Universitätsklinikum Bonn, Bonn, Deutschland

author Bögemann Bögemann M. M

Universitätsklinikum Münster, Münster, Deutschland

author Steuber Steuber T. T

Martini Klinik, Hamburg, Deutschland

author Chun Chun F. F

Universitätsklinikum Frankfurt, Urologie, Frankfurt, Deutschland

author Santoni Santoni M. M

Macareta Krankenhaus, Onkologie, Macerata, Italien

author Mandel Mandel P. P

Universitätsklinikum Frankfurt, Urologie, Frankfurt, Deutschland

author German Medical Science GMS Publishing House

Düsseldorf

610 20260610 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0649 17 Südwestdeutsche Gesellschaft für Urologie e.V. 66. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V. Vortragssitzung 3: Prostatakarzinom I Koblenz 20260610 20260613 V3.1 TextIntroduction: Data for direct comparison of the outcomes for ADT+androgen signaling pathway-inhibitors (ARPI) vs. ADT+ARPI+docetaxel is scant, especially in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) according to CHAARTED-classification and regarding to the number of bone metastases.Method: Relying on the multicentric international ARON-3 database, high-volume mHSPC patients with bone metastases undergoing doublet vs. triplet-therapy were selected and stratified according to the number of bone metastases (≤10 vs. >10). Primary endpoints consisted of time to treatment failure (TTF), PSA-response and overall survival (OS).Results: Overall, 841 patients treated with doublet (75%) or triplet (25%) therapy were included. Patients undergoing triplet-therapy had a higher reduction in opioid use and a higher improvement in ECOG performance status 12 weeks after treatment initiation. Median OS was 63.0 months for ADT+ABI and was not reached for ADT+APA, ADT+ENZA and ADT+DOCE+DARO. In adjusted analyses, triplet therapy was associated with longer TTF and numerically longer OS in patients with >10 bone metastases (HR 0.44, p=0.002 and HR 0.50, p=0.048). In patients with concomitant visceral metastases, triplet therapy was associated with numerically longer TTF and OS, but differences were not statistically significant.Conclusion: The outcome of high-volume mHSPC patients stratified by bone metastatic burden, was more favorable with triplet therapy in the >10 subgroup, whereas no meaningful differences were observed in the ≤10 subgroup. Given the retrospective design and potential residual confounding, prospective validation is warranted. 0 0 0 0